Alivus Life Sciences Limited share price
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also …Read more
- Market Cap₹ 16,077 Cr.
- Current Price₹ 1,309.50
- High / Low₹ 1,494 / 819
- Stock P/E26.1
- Book Value₹ 271
- Dividend Yield0.38 %
- ROCE21.8 %
- ROE18.40 %
- Face Value₹ 2.0
More figures (10)
- EPS (TTM)₹ 50.24
- Price / Book4.83
- OPM28.9 %
- Debt / Equity0.02
- Sales growth (3Y)5.7 %
- Profit growth (3Y)6.5 %
- Promoter holding76.1 %
- EV / EBITDA18.3
- Beta0.07
- All-time high₹ 1,494
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| ALIVUS | -4.46% | +12.49% | +22.25% | +42.86% | +41.00% | +25.15% | +14.80% |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Alivus Life Sciences Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹16,077 crore.
- It trades at 26.1 times its last 12 months' earnings and 4.8 times book value.
- Revenue grew 5.7% a year over the last 3 years, profit 6.5% a year.
- Return on equity was 18.4% and return on capital employed 21.8% in the latest year.
- Debt was 0.02 times shareholders' equity.
- The share price is 12.3% below its 52-week high and up 41.0% over one year.
- Promoters and insiders hold about 76.1%; institutions about 7.3%.
Pros
AI- Strong return on equity: 19.5% on average over the last 3 years.
- Company is almost debt-free (debt is 0.02 times equity).
- Institutional (FII + DII) holding has risen by 7.7 points over 3 years.
Cons
AI- Sales growth has been slow: 5.7% a year over the last 3 years.
- Promoter holding has fallen by 8.00 points over 3 years, to 74.85%.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Alivus Life Sciences Limited
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also provides contract development and manufacturing comprising process development, analytical development and support, and API and intermediate manufacturing; and research and development, intellectual p…
- Employees
- 2,272
- Head office
- Mumbai
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Alivus Life Sciences | 1,309.50 | 26.1 | 16,077 | 0.38 | 160 | 31.71 | 640 | 6.41 | 21.8 | 18.4 | 4.83 | 28.9 | 0.02 | 76.08 | 2,552 | 5.7 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,921 | 54.85 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,980 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 786 | -39.18 | 7,119 | 2.33 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 28,163 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 574 | 29.12 | 4,031 | 12.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 64 Co. | 1,712.85 | 34.1 | 9,915 | 0.18 | 680 | 21.70 | 6,020 | 15.68 | 16.4 | 12.9 | 3.73 | 15.0 | 0.21 | 55.20 | 20,499 | 11.2 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Standalone figures in ₹ crore
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Standalone figures in ₹ crore
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own 3-year sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
- Related Party TransactionsGlenmark Life Sciences Limited has informed the Exchange about related Party Transactions for the half year ended March 31, 202327-Apr-2023
- Related Party TransactionGlenmark Life Sciences Limited has informed the Exchange about related party transaction for the period ended September 202204-Nov-2022
- Related Party TransactionGlenmark Life Sciences Limited has informed the Exchange about related party transaction for the period ended March 31, 2022.31-May-2022
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 | |
| YOY Sales Growth % | 1.79% | 5.64% | 4.54% | 6.91% | ||
| 1,507 | 1,519 | 1,609 | 1,704 | 1,755 | 1,754 | |
| Material Cost % | 49% | 47% | 44% | 45% | 42% | 41% |
| Employee Cost % | 8% | 8% | 11% | 11% | 11% | 11% |
| Other Expenses % | 14% | 15% | 15% | 16% | 16% | 16% |
| Operating Profit | 616 | 642 | 674 | 683 | 797 | 837 |
| OPM % | 29% | 30% | 30% | 29% | 31% | 32% |
| 15 | 29 | 12 | 35 | 60 | 74 | |
| Exceptional items | -26 | -26 | ||||
| Interest | 28 | 1 | 2 | 2 | 5 | 5 |
| Depreciation | 38 | 42 | 53 | 61 | 75 | 79 |
| Profit before tax | 565 | 629 | 631 | 654 | 751 | 801 |
| 26% | 26% | 25% | 26% | 25% | 25% | |
| Current tax | 138 | 151 | 152 | 162 | 184 | |
| Deferred tax | 9 | 11 | 8 | 6 | 3 | |
| 419 | 467 | 471 | 486 | 564 | 603 | |
| YOY Profit Growth % | 11.52% | 0.84% | 3.13% | 16.24% | ||
| EPS in Rs | 35.63 | 38.11 | 38.43 | 39.63 | 45.99 | 49.12 |
| Dividend Payout % | 31% | 83% | 59% | 11% |
Compounded Sales Growth
- 3 Years:
- 6%
- TTM:
- 8%
Compounded Profit Growth
- 3 Years:
- 7%
- TTM:
- 22%
Stock Price CAGR
- 5 Years:
- 15%
- 3 Years:
- 25%
- 1 Year:
- 41%
Return on Equity
- 4 Years:
- 20%
- Last Year:
- 18%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 |
| Reserves | 2,114 | 2,308 | 2,793 | 3,308 |
| Borrowings | 19 | 17 | 57 | 57 |
| 545 | 501 | 537 | 594 | |
| Trade payables | 427 | 369 | 390 | 372 |
| Current liabilities | 497 | 439 | 470 | 508 |
| Total Liabilities | 2,702 | 2,850 | 3,411 | 3,983 |
| 826 | 905 | 1,046 | 1,297 | |
| Gross block | 977 | 1,104 | 1,299 | 1,613 |
| Accumulated depreciation | 152 | 199 | 254 | 316 |
| Goodwill & intangibles | 18 | 15 | 20 | 30 |
| CWIP | 51 | 110 | 103 | 279 |
| 1,826 | 1,836 | 2,263 | 2,407 | |
| Inventories | 604 | 667 | 674 | 692 |
| Trade receivables | 807 | 765 | 970 | 1,073 |
| Cash & equivalents | 284 | 301 | 71 | 2 |
| Current assets | 1,850 | 1,916 | 2,335 | 2,649 |
| Total Assets | 2,702 | 2,850 | 3,411 | 3,983 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 306 | 414 | 392 | 565 | |
| Profit for the year | 467 | 471 | 486 | 564 |
| Working capital changes | -214 | -134 | -180 | -129 |
| Direct taxes paid | -154 | -163 | -163 | -173 |
| -147 | -116 | -616 | -570 | |
| Fixed assets purchased | -163 | -129 | -166 | -307 |
| Fixed assets sold | 0 | 0 | 1 | 1 |
| Investments purchased | -470 | -495 | ||
| Investments sold | 0 | 230 | ||
| -388 | -279 | -6 | -64 | |
| Interest paid | -1 | -2 | -2 | -5 |
| Dividends paid | -386 | -276 | -61 | |
| Net Cash Flow | -228 | 18 | -230 | -69 |
| Free Cash Flow | 143 | 285 | 225 | 258 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 21.8% | 21.1% | 18.9% | 18.4% |
| ROCE | — | 28.5% | 26.2% | 22.3% | 21.8% |
| Operating margin | — | 29.3% | 28.5% | 26.7% | 28.9% |
| Net margin | — | 22.8% | 21.6% | 20.8% | 22.5% |
| Debt / equity | — | 0.01 | 0.01 | 0.02 | 0.02 |
| Current ratio | — | 3.73 | 4.37 | 4.97 | 5.21 |
| Debtor days | — | 144 | 128 | 151 | 156 |
| Inventory days | — | 214 | 238 | 220 | 226 |
| Days payable | — | 151 | 132 | 127 | 122 |
| Cash conversion cycle | — | 207 | 234 | 244 | 260 |
| Working capital days | — | 241 | 247 | 291 | 312 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 74.85%
- FIIs 5.93%
- DIIs 7.03%
- Public 12.19%
| % | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 82.85% | 82.85% | 82.85% | 75.00% | 75.00% | 74.99% | 74.94% | 74.91% | 74.91% | 74.87% | 74.87% | 74.85% |
| 4.57% | 5.01% | 4.82% | 7.85% | 6.74% | 6.57% | 6.42% | 6.84% | 5.09% | 5.29% | 5.54% | 5.93% | |
| Foreign portfolio investors (Cat. I) | 4.34% | 4.70% | 4.54% | 7.20% | 6.23% | 6.24% | 6.20% | 6.73% | 4.96% | 5.18% | 5.39% | 5.62% |
| Foreign portfolio investors (Cat. II) | 0.23% | 0.31% | 0.27% | 0.65% | 0.51% | 0.33% | 0.22% | 0.11% | 0.12% | 0.12% | 0.15% | 0.31% |
| 0.74% | 1.40% | 1.57% | 4.16% | 4.86% | 5.19% | 5.61% | 5.47% | 7.12% | 7.28% | 7.18% | 7.03% | |
| Mutual funds | 0.59% | 0.93% | 1.01% | 2.82% | 3.23% | 3.59% | 4.06% | 3.87% | 5.44% | 5.63% | 5.65% | 5.29% |
| Insurance companies | 0.08% | 0.22% | 0.22% | 0.18% | 0.24% | 0.27% | 0.27% | 0.27% | 0.24% | |||
| Alternative investment funds | 0.15% | 0.48% | 0.56% | 1.26% | 1.41% | 1.38% | 1.38% | 1.36% | 1.42% | 1.37% | 1.26% | 1.50% |
| 11.84% | 10.73% | 10.76% | 12.98% | 13.40% | 13.25% | 13.03% | 12.78% | 12.88% | 12.56% | 12.41% | 12.19% | |
| Retail (up to ₹2 lakh) | 8.57% | 8.46% | 8.50% | 9.89% | 10.05% | 9.76% | 9.59% | 9.39% | 9.46% | 9.12% | 9.30% | 9.00% |
| HNIs (above ₹2 lakh) | 0.63% | 0.63% | 0.63% | 0.74% | 0.94% | 0.74% | 0.74% | 0.75% | 0.75% | 0.75% | 0.75% | 1.11% |
| NRIs | 0.42% | 0.53% | 0.52% | 0.68% | 0.68% | 0.66% | 0.64% | 0.67% | 0.68% | 0.72% | 0.69% | 0.64% |
| Bodies corporate | 1.95% | 0.88% | 0.87% | 1.39% | 1.41% | 1.79% | 1.72% | 1.62% | 1.65% | 1.57% | 1.27% | 1.17% |
| No. of Shareholders | 1,85,531 | 1,56,183 | 1,49,396 | 1,43,960 | 1,46,840 | 1,41,977 | 1,38,500 | 1,35,643 | 1,32,748 | 1,27,969 | 1,25,559 | 1,22,777 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Mutual funds & institutions holding Alivus Life Sciences
| Holder (above 1%) | Stake |
|---|---|
| Quant Small Cap FundMutual fund | 2.85% |
| Old Bridge Focused FundMutual fund | 1.07% |
As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 5.29% of the company. Shareholders below 1% are not named in the filing.
Documents
Announcements
- General UpdatesAlivus Life Sciences Limited has informed the Exchange about General Updates09-Oct-2026
- General UpdatesAlivus Life Sciences Limited has informed the Exchange about announcement under Regulation 30 of SEBI (LODR), 2015 - Acquisition.07-Oct-2026
- General UpdatesAlivus Life Sciences Limited has informed the Exchange that the Company has incorporated a wholly owned subsidiary company in Brazil.16-Sep-2026
- Shareholders meetingAlivus Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 08, 2026. Further, the company has submitted the Exchange …08-Sep-2026
- Press ReleaseAlivus Life Sciences Limited has informed the Exchange regarding a press release dated August 18, 2026, titled "Alivus Life Sciences announces acquisition of majority stake in IQG…18-Aug-2026
- Outcome of Board MeetingEnclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.18-Aug-2026
- Copy of Newspaper PublicationAlivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 15th Annual General Meeting and e-voting information.13-Aug-2026
- UpdatesAlivus Life Sciences Limited has informed the Exchange regarding 'Business Responsibility & Sustainability Report for FY 2025-26'.11-Aug-2026
- Shareholders meetingAlivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting (AGM) to be held on September 8, 2026. Enclosed please find herewith Notice of th…11-Aug-2026
- Copy of Newspaper PublicationAlivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication regarding intimation of 15th AGM.06-Aug-2026
- Record DateAlivus Life Sciences Limited has informed the Exchange that Record date for the purpose of Dividend is 01-Sep-2026.06-Aug-2026
- Shareholders meetingAlivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 08, 202606-Aug-2026
Annual reports
- Financial Year 202611-AUG-2026
- Financial Year 202512-AUG-2025
- Financial Year 202402-SEP-2024
- Financial Year 2023
- Financial Year 2022
Credit ratings
- Credit Rating- RevisionAlivus Life Sciences Limited has informed the Exchange about Credit Rating- Revision16-Sep-2025
- Credit RatingGlenmark Life Sciences Limited has informed the Exchange about Credit Rating19-Jun-2024
- Credit RatingGlenmark Life Sciences Limited has informed the Exchange about Credit Rating04-Oct-2023
Concalls & investor meets
- Analysts/Institutional Investor Meet/Con. Call UpdatesAlivus Life Sciences Limited has informed the Exchange about Schedule of meet11-Sep-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAlivus Life Sciences Limited has informed the Exchange about Schedule of meet07-Sep-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAlivus Life Sciences Limited has informed the Exchange about Schedule of meet05-Sep-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAlivus Life Sciences Limited has informed the Exchange about Schedule of Investor/Analyst meeting25-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAlivus Life Sciences Limited has informed the Exchange about Schedule of meet of Investor/Analyst.13-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAlivus Life Sciences Limited has informed the Exchange about Schedule of meet07-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAlivus Life Sciences Limited has informed the Exchange about Schedule of meet07-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAlivus Life Sciences Limited has informed the Exchange about Transcript of earnings call held on July 31, 2026.07-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAlivus Life Sciences Limited has informed the Exchange about Link of Recording31-Jul-2026
- Investor PresentationAlivus Life Sciences Limited has informed the Exchange about Investor Presentation30-Jul-2026
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 1 Sep 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
No recent coverage found.
From the company (NSE)
- General UpdatesAlivus Life Sciences Limited has informed the Exchange about General UpdatesNSE filing · 09-Oct-2026
- General UpdatesAlivus Life Sciences Limited has informed the Exchange about announcement under Regulation 30 of SEBI (LODR), 2015 - Acquisition.NSE filing · 07-Oct-2026
- General UpdatesAlivus Life Sciences Limited has informed the Exchange that the Company has incorporated a wholly owned subsidiary company in Brazil.NSE filing · 16-Sep-2026
- Shareholders meetingAlivus Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 08, 2026. Further, the company has submitted the Exchange …NSE filing · 08-Sep-2026
- Press ReleaseAlivus Life Sciences Limited has informed the Exchange regarding a press release dated August 18, 2026, titled "Alivus Life Sciences announces acquisition of majority stake in IQG…NSE filing · 18-Aug-2026
- Outcome of Board MeetingEnclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.NSE filing · 18-Aug-2026
- Copy of Newspaper PublicationAlivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 15th Annual General Meeting and e-voting information.NSE filing · 13-Aug-2026
- UpdatesAlivus Life Sciences Limited has informed the Exchange regarding 'Business Responsibility & Sustainability Report for FY 2025-26'.NSE filing · 11-Aug-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Alivus Life Sciences Limited
What is the share price of Alivus Life Sciences Limited today?
What is the market cap of Alivus Life Sciences Limited?
What is the P/E ratio of Alivus Life Sciences Limited?
Is Alivus Life Sciences Limited a good investment?
How can I buy Alivus Life Sciences Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.